Compare T-Rex 2X Long MSTR Daily Target ETF (MSTU) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Long MSTR Daily Target ETF vs TG Therapeutics Inc — how do they compare? T-Rex 2X Long MSTR Daily Target ETF trades at $2.14, while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| MSTU | TGTX | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $92.70 | $59.06 |
52-Week Low | $1.46 | $26.39 |
Market Cap | — | $8.26B |
Enterprise Value | — | $8.50B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
